<SEC-DOCUMENT>0001571049-16-013771.txt : 20160411
<SEC-HEADER>0001571049-16-013771.hdr.sgml : 20160411
<ACCEPTANCE-DATETIME>20160411090439
ACCESSION NUMBER:		0001571049-16-013771
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20160329
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160411
DATE AS OF CHANGE:		20160411

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		161564028

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>t1600976_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>FORM 8-K </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>CURRENT REPORT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Pursuant to Section 13 or 15(d) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>of the Securities Exchange Act of 1934 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Date of Report (Date of earliest event reported):
March 29, 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 18pt"><B>CYCLACEL
PHARMACEUTICALS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>(Exact name of registrant as specified in
its charter) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 34%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>0-50626</B></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>91-1707622</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(State or other jurisdiction</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(Commission File Number)</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(IRS Employer</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>of incorporation)</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Identification No.)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>200 Connell
Drive, Suite 1500</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Berkeley Heights, NJ 07922 </B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>(Address of principal executive offices and zip code) </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Registrant&rsquo;s telephone number, including
area code: (908) 517-7330</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>(Former Name or Former Address, if Changed
Since Last Report)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see </I>General
Instruction A.2. below): </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD>
    <TD STYLE="width: 97%"><FONT STYLE="font-size: 10pt"><B>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </B></FONT></TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD>
    <TD STYLE="width: 97%"><FONT STYLE="font-size: 10pt"><B>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </B></FONT></TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD>
    <TD STYLE="width: 97%"><FONT STYLE="font-size: 10pt"><B>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </B></FONT></TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD>
    <TD STYLE="width: 97%"><FONT STYLE="font-size: 10pt"><B>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: black 1pt solid"><B>Item 8.01 Other Events.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Declaration of Quarterly Cash Dividend on 6% Convertible Exchangeable
Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On March 29, 2016, the Board of Directors (the
&ldquo;<B>Board</B>&rdquo;) of Cyclacel Pharmaceuticals, Inc. (the &ldquo;<B>Company</B>&rdquo;) declared a quarterly cash dividend
in the amount of $0.15 per share on the Company&rsquo;s 6% Convertible Exchangeable Preferred Stock (&ldquo;<B>Preferred Stock</B>&rdquo;).
The cash dividend will be payable on May 1, 2016 to the holders of record of the Preferred Stock as of the close of business on
April 18, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Board considered numerous factors in determining
whether to declare the quarterly dividend, including the requisite financial analysis and determination of a surplus. While the
Board will analyze the advisability of the declaration of dividends in future quarters, there is no assurance that future quarterly
dividends will be declared.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Receipt of NASDAQ Extension</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">As previously disclosed, on February 2, 2016,
the Company received a letter from the Listing Qualifications Staff of The NASDAQ Stock Market LLC (&ldquo;<B>NASDAQ</B>&rdquo;)
notifying it that, because it had not regained compliance with the $1.00 minimum bid price requirement for continued listing as
set forth in NASDAQ Listing Rule 5550(a)(2) (the &ldquo;<B>Rule</B>&rdquo;), its common stock would be subject to delisting from
NASDAQ unless the Company timely requested a hearing before a NASDAQ Listing Qualifications Panel (the &ldquo;<B>Pane</B>l&rdquo;).
The Company requested a hearing before the Panel, at which it presented a plan to regain compliance with the Rule and requested
that the Panel allow it additional time to implement the plan. On April 4, 2016, the Panel rendered its written decision granting
the Company until June 14, 2016 to regain compliance with the Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On April 11, 2016, the Company issued a press
release announcing that it had received a favorable ruling from the Panel, whereby the Panel has granted its request to remain
listed on The NASDAQ Capital Market, subject to the condition that on or before June 14, 2016, it must have evidenced a closing
bid price of $1.00 per share or more for a minimum of ten prior consecutive trading days.&nbsp; The full text of the press release
is attached to this current report on Form 8-K as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: black 1pt solid"><B>Item 9.01 Financial Statements
and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(d) Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD NOWRAP STYLE="vertical-align: top; width: 10%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 8pt"><B>Exhibit</B></FONT><BR>
<FONT STYLE="font-size: 8pt"><B>Number</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; width: 89%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 8pt"><B>Description</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Press release announcing ruling from the NASDAQ Listing Qualifications Panel, dated April 11, 2016.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>CYCLACEL PHARMACEUTICALS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="width: 43%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Paul McBarron</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Paul McBarron</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Executive Vice President&mdash;Finance, </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer and Chief Operating Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: April 11, 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>t1600976_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 50%; font: 12pt Times New Roman,serif"><IMG SRC="logo1.jpg" ALT=""></td>
    <TD STYLE="width: 50%; font: 12pt Times New Roman,serif; text-align: right; vertical-align: middle"><font style="font-family: Arial,sans-serif; font-size: 10pt">Cyclacel Pharmaceuticals, Inc.</font></td></tr>
</table>
<P STYLE="font: 12pt Times New Roman,serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman,serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="logo2.jpg" ALT=""></P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0 0pt 5pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Cyclacel
Announces Receipt of NASDAQ Extension</B></FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Berkeley Heights, NJ,
April 11, 2016</B> - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; (&ldquo;Cyclacel&rdquo; or the &ldquo;Company&rdquo;)
a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of
cancer and other serious disorders, today announced that the Company received a written ruling from the NASDAQ Hearings Panel (the
&ldquo;Panel&rdquo;) stating that the Panel has granted the Company&rsquo;s request to remain listed on The NASDAQ Capital Market.</P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify; background-color: white">Cyclacel&rsquo;s continued
listing on NASDAQ is conditioned upon the Company demonstrating compliance with the minimum bid price requirement, as set forth
in Listing Rule 5550(a)(2), by June 14, 2016, and also remaining in compliance on that date with NASDAQ&rsquo;s other continued
listing requirements. Specifically, the Company must evidence a closing bid price for its common stock of at least $1.00 per share
for a minimum of 10 consecutive business days by the close of business on June 14, 2016. The Panel&rsquo;s favorable determination
follows a hearing that took place on March 31, 2016.</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify">The Company has included a proposal in its Preliminary
Proxy Statement filed with the Securities and Exchange Commission on March 30, 2016 asking its stockholders to approve a reverse
split of the Company&rsquo;s common stock in order to maintain the listing of its common stock on The NASDAQ Capital Market. The
stockholder vote on the reverse stock split proposal will be announced at the Company&rsquo;s 2016 Annual Meeting of Stockholders,
to be held on May 26, 2016 at the Company&rsquo;s corporate headquarters in Berkeley Heights, New Jersey. The Company must regain
compliance with the minimum bid price requirement no later than ten trading days prior to June 14, 2016. Should the company be
unable to meet the requirements of the Panel's decision by June 14, 2016, the Panel will issue a final delist determination and
immediately suspend all trading in Cyclacel&rsquo;s shares of common stock on The NASDAQ Capital Market.</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0"><B>About Cyclacel Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify; background-color: white">Cyclacel is a biopharmaceutical
company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious
diseases. Sapacitabine, Cyclacel's most advanced product candidate, is the subject of SEAMLESS, a Phase 3 trial, which has completed
enrollment and is being conducted under an SPA with the U.S. Food and Drug Administration (FDA) as front-line treatment for acute
myeloid leukemia (AML) in the elderly, and other indications, including myelodysplastic syndromes (MDS). Cyclacel's pipeline includes
an oral regimen of seliciclib in combination with sapacitabine in a Phase 1 study of patients with solid tumors, including BRCA
positive cancers, and CYC065, a novel CDK2/9 inhibitor, in a Phase 1 study of patients with solid tumors and lymphomas with potential
utility in both hematological malignancies and solid tumors. Cyclacel's strategy is to build a diversified biopharmaceutical business
focused in hematology and oncology based on a development pipeline of novel drug candidates. Please visit <U>www.cyclacel.com</U>
for more information.</P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&thorn;</FONT><FONT STYLE="font-family: Arial,sans-serif; font-size: 8pt">
200 Connell Drive, Suite 1500, Berkeley Heights, New Jersey 07922, USA Tel +1 (908) 517 7330 Fax +1 866 271 3466</FONT></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT><FONT STYLE="font-family: Arial,sans-serif; font-size: 8pt">
Dundee Technopole, James Lindsay Place, Dundee, DD1 5JJ, UK Tel +44 1382 206 062 Fax +44 1382 206 067</FONT></P>

<P STYLE="font: 7pt Arial,sans-serif; margin: 0pt 0; text-align: center"><U>www.cyclacel.com</U>&nbsp;&nbsp;&ndash;&nbsp;&nbsp;<U>info@cyclacel.com</U></P>

<P STYLE="font: 7pt Arial,sans-serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0"><B>Forward-looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify; background-color: white">This news release contains
certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different
from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking
statements include statements regarding, among other things, the efficacy, safety and intended utilization of Cyclacel's product
candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical
trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that
product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale
or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates,
the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on
collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider
statements that include the words &quot;may,&quot; &quot;will,&quot; &quot;would,&quot; &quot;could,&quot; &quot;should,&quot;
&quot;believes,&quot; &quot;estimates,&quot; &quot;projects,&quot; &quot;potential,&quot; &quot;expects,&quot; &quot;plans,&quot;
&quot;anticipates,&quot; &quot;intends,&quot; &quot;continues,&quot; &quot;forecast,&quot; &quot;designed,&quot; &quot;goal,&quot;
or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description
of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic
and other filings we file with the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements
are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as
a result of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0"><B>Contacts for Cyclacel Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify; background-color: white">Company:<BR>
Paul McBarron, (908) 517-7330, <FONT STYLE="color: Black"><U>pmcbarron@cyclacel.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0">Investor Relations/Media:<BR>
Russo Partners LLC, Robert Flamm, (212) 845-4226, <FONT STYLE="color: Black"><U>robert.flamm@russopartnersllc.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 11pt Calibri,sans-serif; margin: 0pt 0; text-align: justify">&copy; Copyright 2016 Cyclacel Pharmaceuticals, Inc.
All Rights Reserved. The Cyclacel logo and Cyclacel&reg; are trademarks of Cyclacel Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 1 "U P$1  (1 0,1 ?_$ *<  0 " P$! 0$
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MVOT(K?Q"WB4N.6^(+2?L(ZUYL\B?7)O;<<]6#XBQ_LHRE%+;[K7N9KOP4W'
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M?N;=N=W4\R<Q+DRHT1!:CA]?J+;9U72@KL-2K6U+/51'PL!NG9NQ=L[(C/C
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44IQ2G%*<4IQ2G%*<4IQ2G%*__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>logo2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo2.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ & ). P$1  (1 0,1 ?_$ &\  0 " @,! 0
M       '" 8) P0% 0H! 0                     0   % P,$ @$$ 04!
M      $" P0%  8'$576$I<(&"$3%#%!(A51,B,S%A<E$0$
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H2BVB;YX)[#OM(Q6RK]G&D,D16W"'<J?EOT@$B8'.!1$XAT%,8 __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
